Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
July 27, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at...
Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
June 14, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an...
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
June 08, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS)...
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 28, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman...
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
May 21, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th...
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
May 10, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Galafold® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M 1Q21 Total Galafold Revenue of $66.4M Driven by...
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
May 07, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the...
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
May 06, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE...
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 05, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy...
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
May 03, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
Existing Data Support Regulatory Submissions Submissions to Seek Approval in both ERT Naïve and ERT Switch Pompe Patients Completion of Rolling Biologics License Application On-Track by end of 2Q21...